HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and maintains $11 price target.
HC Wainwright & Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and maintains $11 price target.